Cost-effectiveness of TAVI in the United Kingdom: a long-term analysis based on 4-year data from the Evolut Low Risk Trial
Recent 4-year follow-up data from the Evolut Low Risk trial suggest TAVI adds meaningful patient benefit over lifetime and can be expected to be a cost-effective intervention compared to SAVR for low surgical risk patients in a UK setting.
Authors
- Jan B. Pietzsch (ORCID: https://orcid.org/0000-0002-5078-1939)
- Abigail M. Garner
- John K. Forrest (ORCID: https://orcid.org/0000-0003-4079-3482)
- Daniel J. Blackman (ORCID: https://orcid.org/0000-0001-9039-6130)
- Michael J. Reardon (ORCID: https://orcid.org/0000-0002-2880-6132)
- Anne M. Ryschon
- Sophie Barnett (ORCID: https://orcid.org/0009-0001-5362-172X)
Institutions
- Houston Methodist (US)
- University of Leeds (GB)
- Leeds Teaching Hospitals NHS Trust (GB)
- Medtronic (Ireland) (IE)
- Yale University (US)
- Minnesota State College-Southeast Technical (US)
Publication Details
- Journal
- The European Journal of Health Economics
- Published
- 2024-11-23
- DOI
- https://doi.org/10.1007/s10198-024-01739-2
- Citations
- 2
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Edwards Lifesciences
- Boston Scientific Corporation
- Medtronic
- Medtronic Europe
- Abbott Vascular